Search research articles
Contact Us
Filters
Showing results (31-40 of 47) with videos related to
Page
of 5
Sort By:
Stem Cells Translational Medicine
|
June 13, 2023
Fate and Efficacy of Engineered Allogeneic Stem Cells Targeting Cell Death and Proliferation Pathways in Primary and Brain Metastatic Lung Cancer
Susana Moleirinho, Yohei Kitamura, Paulo S G N Borges, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 25, 2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials
Jason Grebely, Stefan Mauss, Ashley Brown, et al.
The Journal of Infectious Diseases
|
June 8, 2014
Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response
Jennifer C Lin, François Habersetzer, Maribel Rodriguez-Torres, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 27, 2012
Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
Jeroen A J M van de Water, Tugba Bagci-Onder, Aayush S Agarwal, et al.
Journal of Hepatology
|
April 19, 2022
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
Naim Alkhouri, Robert Herring, Heidi Kabler, et al.
Hepatology (Baltimore, Md.)
|
December 21, 2016
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection
William F Balistreri, Karen F Murray, Philip Rosenthal, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 31, 2016
Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities
Samuel B Ho, Alexander Monto, Adam Peyton, et al.
Breast Cancer Research and Treatment
|
May 11, 2022
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Joyce O'Shaughnessy, Adam Brufsky, Hope S Rugo, et al.
Hepatology (Baltimore, Md.)
|
November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data
Julius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
NPJ Breast Cancer
|
June 10, 2022
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis
Lisa A Carey, Delphine Loirat, Kevin Punie, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 47) with videos related to
Sort By:
Page
of 5
Stem Cells Translational Medicine
|
June 13, 2023
Fate and Efficacy of Engineered Allogeneic Stem Cells Targeting Cell Death and Proliferation Pathways in Primary and Brain Metastatic Lung Cancer
Susana Moleirinho, Yohei Kitamura, Paulo S G N Borges, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 25, 2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials
Jason Grebely, Stefan Mauss, Ashley Brown, et al.
The Journal of Infectious Diseases
|
June 8, 2014
Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response
Jennifer C Lin, François Habersetzer, Maribel Rodriguez-Torres, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 27, 2012
Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
Jeroen A J M van de Water, Tugba Bagci-Onder, Aayush S Agarwal, et al.
Journal of Hepatology
|
April 19, 2022
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
Naim Alkhouri, Robert Herring, Heidi Kabler, et al.
Hepatology (Baltimore, Md.)
|
December 21, 2016
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection
William F Balistreri, Karen F Murray, Philip Rosenthal, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 31, 2016
Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities
Samuel B Ho, Alexander Monto, Adam Peyton, et al.
Breast Cancer Research and Treatment
|
May 11, 2022
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Joyce O'Shaughnessy, Adam Brufsky, Hope S Rugo, et al.
Hepatology (Baltimore, Md.)
|
November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data
Julius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
NPJ Breast Cancer
|
June 10, 2022
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis
Lisa A Carey, Delphine Loirat, Kevin Punie, et al.
Page
of 5